<DOC>
	<DOCNO>NCT02248402</DOCNO>
	<brief_summary>Multiple myeloma remain incurable disease patient . Cellular immunotherapy use dendritic cell emerge useful immunotherapeutic modality treat multiple myeloma . Vax-DC/MM potent immunotherapeutic agent generate dendritic cell loaded ultraviolet B-irradiated autologous human myeloma cell . The main purpose study examine safety efficacy Vax-DC/MM patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Autologous Dendritic Cell Therapy Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>- To create Vax-DC/MM , myeloma cell obtain bone marrow participant , leukapheresis perform obtain dendritic cell - Not everyone participant study receive dose study vaccine . A small group patient enrol study give certain dose . If tolerate , next group patient enrol receive high dose . - Before first injection Vax-DC , low dose cyclophosphamide administer stimulate immune response . - Participants receive certain dose Vax-DC weekly four time .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Relapsed refractory multiple myeloma receive least one prior therapy include thalidomide , bortezomib , lenalidomidecontaining regimen Subjects measurable disease define least one follow Serum Mprotein ≥ 1.0 g/dL Urine Mprotein ≥ 400 mg/24hr Eastern Cooperative Oncology Group Performance Status ≤ 2 Hemoglobin ≥ 8 g/dL ( ≥ 4.96 mol/L ) : Prior red blood cell transfusion recombinant human erythropoietin use allow . Absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L Aspartate aminotransferase ( AST ) &lt; 3 time upper limit normal Alanine aminotransferase ( ALT ) &lt; 3 time upper limit normal Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Smoldering indolent myeloma Uncontrolled severe cardiovascular disease ( cardiac ejection fraction &lt; 0.5 , Severe conduction disorder ) Sepsis current active infection Pregnancy breastfeed Received immunotherapy treatment Clinically significant autoimmune disease Serious medical psychiatric illness likely interfere participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>